Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 10 May 2022
Calls for Health Minister to release final report from PHARMAC review
11 May 2022 - Health Minister Andrew Little is facing calls to release the final report from a review of ...
Posted by Michael Wonder on 10 May 2022
Exit Aduhelm, enter lecanemab. Biogen and Eisai have another go
10 May 2022 - Here we go again. With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better ...
Posted by Michael Wonder on 10 May 2022
Democrats’ drug pricing plan is the wrong prescription for inflation
10 May 2022 - Gas prices are high, everyday household goods are growing more expensive and grocery store receipts are ...
Posted by Michael Wonder on 10 May 2022
FDA launches new Accelerating Rare disease Cures (ARC) program
10 May 2022 - FDA’s Center for Drug Evaluation and Research (CDER) is pleased to announce the launch of the new ...
Posted by Michael Wonder on 10 May 2022
FDA approves treatment for COVID-19 in certain hospitalised adults
10 May 2022 - Today, the FDA approved a new indication for Olumiant (baricitinib) for the treatment of COVID-19 in hospitalised ...
Posted by Michael Wonder on 10 May 2022
Turning Point Therapeutics granted breakthrough therapy designation for repotrectinib treatment in patients with one prior ROS1 tyrosine kinase inhibitor and no prior chemotherapy
10 May 2022 - Turning Point Therapeutics today announced the U.S. FDA granted an eighth regulatory designation, and third breakthrough therapy ...
Posted by Michael Wonder on 10 May 2022
Fertility drug Rekovelle gets reimbursable in combo with hMG
10 May 2022 - Ferring’s Rekovelle (follitropin delta), a treatment to promote egg production in ovaries, became reimbursable when used ...
Posted by Michael Wonder on 10 May 2022
ICER publishes final evidence report and policy recommendations on outpatient treatments for COVID-19
10 May 2022 - Independent appraisal committee votes 11-2 that the evidence is not adequate to demonstrate a net health benefit ...
Posted by Michael Wonder on 10 May 2022
HIRA unveils detailed reimbursement criteria for Olumiant, Rinvoq
10 May 2022 - Lilly’s Olumiant (baricitinib) and Abbvie’s Rinvoq (upadacitinib) got health insurance benefits starting from May 1 to ...
Posted by Michael Wonder on 10 May 2022
First treatment option indicated for CKD in Scotland for 20 years
10 May 2022 - NICE recommendation for Forxiga could entitle 53,000 adults to the new kidney disease therapy ...
Posted by Michael Wonder on 10 May 2022
High-risk COVID-19 patients can now get two antiviral prescription drugs — but some are still missing out
10 May 2022 - For Australians at high risk of developing severe COVID-19, getting access to potentially lifesaving treatment recently ...
Posted by Michael Wonder on 10 May 2022
Eisai completes rolling submission to the U.S. FDA for biologics license application of lecanemab for early Alzheimer's disease under the accelerated approval pathway
10 May 2022 - Eisai and Biogen announced today that Eisai has completed the rolling submission to the U.S. FDA of ...
Posted by Michael Wonder on 09 May 2022
Health economic assessment of Abecma in the treatment of multiple myeloma
6 May 2022 - TLV has produced a health economic assessment for the regions for Abecma (idecabtagene vicleucel). ...
Posted by Michael Wonder on 09 May 2022
The Center for Medicare and Medicaid Innovation - toward value based care
9 May 2022 - Before the enactment of the Patient Protection and Affordable Care Act in 2010, experimentation with Medicare or ...
Posted by Michael Wonder on 09 May 2022
Health economic assessment of Blenrep in the treatment of multiple myeloma
6 May 2022 - TLV has produced a health economic assessment for the regions for the drug Blenrep (belantamab mafodotin). ...